Acasti Pharma Inc (ACST) 0.44 $ACST
Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune
GlobeNewswire - Thu Feb 05, 6:28AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), announce the transition of Dr. Tina Sampalis from Chief Global Strategic Officer to a consulting role as Medical Science Liaison for Neptune, starting immediately.
ACST: 0.44 (unch), NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06), APO.VN: 0.530 (-0.020)
Acasti Pharma ups earnings by 177% in FQ3
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 7:26AM CST
ACST: 0.44 (unch)
Acasti Pharma net income of $3.01M
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 4:12PM CST
ACST: 0.44 (unch)
Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 13, 4:05PM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its results for the three and nine-months ended November 30, 2014.
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
High Triglyceridemia - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pnv28/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acasti Pharma - Actavis - Alnylam - Arisaph - Astellas Pharma - AstraZeneca - Cardax Pharmaceuticals - Catabasis Pharmaceuticals - Essentialis - Isis Pharmaceuticals - Novartis - Pharmena - Poxel - Tekmira Pharmaceuticals - Thetis Pharmaceuticals - Trygg Pharma For more information visit http://www.researchandmarkets.com/research/4pnv28/high
ACST: 0.44 (unch), ISIS: 63.86 (-0.43), TKMR: 21.45 (-0.22), NVS: 102.20 (-0.17)
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
GlobeNewswire - Tue Nov 11, 7:01AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that on November 7, 2014 it received notification from the NASDAQ Listing Qualifications Department for failing to maintain a minimum bid price of US$1.00 per share for the last 30 consecutive business days, as required by NASDAQ Listing Rule 5550(a)(2) - bid price.
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti Announces Grant of Stock Options
GlobeNewswire - Mon Oct 20, 6:59AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the grant of an aggregate of 180,000 incentive stock options under the Corporation's Stock Option Plan for its senior executive and management team. Each option will vest gradually over a period of two years and will entitle its holder to purchase one common share of Acasti at a price of CDN $0.65 until October 19, 2019.
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti posts higher Q2 net loss of USD3.712m
M2 - Wed Oct 15, 6:52AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) stated on Tuesday that its net loss was USD3.712m for the three-months ended 31 August 2014.
ACST: 0.44 (unch)
Acasti posts 2Q loss
Automated Insights - Wed Oct 15, 4:03AM CDT
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Tuesday reported a loss of $3.3 million, or 3 cents per share, in its fiscal second quarter.
ACST: 0.44 (unch)
Acasti Announces Second Quarter Results
GlobeNewswire - Tue Oct 14, 6:53AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its results for the three and six-months ended August 31, 2014.
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti Announces Positive Top-Line Pharmacokinetic Results
GlobeNewswire - Tue Sep 30, 7:01AM CDT
-- CaPre(R) demonstrated a near dose proportional increase with plasma EPA and DHA levels increasing as dose increases
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
GlobeNewswire - Mon Sep 29, 7:00AM CDT
-- Statistically significant mean placebo-adjusted reduction of triglycerides of 36.4% at 1 gram and 38.6% at 2 gram daily doses of CaPre(R)
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Mallinckrodt Beats on Q3 Earnings and Revenues, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:23PM CDT
Shares of Mallinckrodt plc (MNK) gained 0.46% following the company's third quarter fiscal 2014 (ended Jun 27, 2014) earnings report last week.
MNK: 115.01 (+2.51), ACST: 0.44 (unch), AKRX: 47.28 (-0.25), ACUR: 0.55 (+0.01)
Acasti Pharma (ACST) Jumps: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:46AM CDT
Acasti Pharma (ACST) was a big mover last session, with shares rising over 7% on the day.
MNK: 115.01 (+2.51), ACST: 0.44 (unch), AKRX: 47.28 (-0.25), RDY: 54.15 (-0.01)
Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston
GlobeNewswire - Thu Jul 24, 6:01AM CDT
-- Phase II Open Label Trial results for prescription drug candidate, CaPre(R) to be presented on July 26, 2014 at 12:30 p.m.
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti swings to Q1 net income of USD1.356m
M2 - Wed Jul 16, 7:41AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) stated on Wednesday its net income of USD1.356m for the first quarter ended 31 May 2014.
ACST: 0.44 (unch)
Acasti Announces First Quarter Results
GlobeNewswire - Wed Jul 16, 3:53AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its financial results for the first quarter ended May 31, 2014.
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti Pharma Inc. (ACST) Jumps: Stock Rises 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:21AM CDT
Acasti Pharma Inc. (ACST) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
CPXX: 3.10 (+0.07), MNK: 115.01 (+2.51), ACST: 0.44 (unch), AKRX: 47.28 (-0.25)
Why Acasti Pharmaceuticals (ACST) Stock Is Up Today
at The Street - Wed Jul 09, 10:48AM CDT
Acasti Pharmaceuticals (ACST) surged Wednesday after the biopharmaceutical company announced it had completed two trials.
ACST: 0.44 (unch)
Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials
GlobeNewswire - Wed Jul 09, 7:09AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the completion of two trials, the Phase II double-blind, placebo-controlled (TRIFECTA) study and the Pharmacokinetic (PK) trial.
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune
GlobeNewswire - Thu Feb 05, 6:28AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), announce the transition of Dr. Tina Sampalis from Chief Global Strategic Officer to a consulting role as Medical Science Liaison for Neptune, starting immediately. ACST: 0.44 (unch), NTB.TO: 2.29 (+0.08), NEPT: 1.83 (+0.06), APO.VN: 0.530 (-0.020)
Acasti Pharma ups earnings by 177% in FQ3
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 7:26AM CST
ACST: 0.44 (unch)
Acasti Pharma net income of $3.01M
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 4:12PM CST
ACST: 0.44 (unch)
Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 13, 4:05PM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its results for the three and nine-months ended November 30, 2014. ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
High Triglyceridemia - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pnv28/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acasti Pharma - Actavis - Alnylam - Arisaph - Astellas Pharma - AstraZeneca - Cardax Pharmaceuticals - Catabasis Pharmaceuticals - Essentialis - Isis Pharmaceuticals - Novartis - Pharmena - Poxel - Tekmira Pharmaceuticals - Thetis Pharmaceuticals - Trygg Pharma For more information visit http://www.researchandmarkets.com/research/4pnv28/high
ACST: 0.44 (unch), ISIS: 63.86 (-0.43), TKMR: 21.45 (-0.22), NVS: 102.20 (-0.17)
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
GlobeNewswire - Tue Nov 11, 7:01AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that on November 7, 2014 it received notification from the NASDAQ Listing Qualifications Department for failing to maintain a minimum bid price of US$1.00 per share for the last 30 consecutive business days, as required by NASDAQ Listing Rule 5550(a)(2) - bid price. ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti Announces Grant of Stock Options
GlobeNewswire - Mon Oct 20, 6:59AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the grant of an aggregate of 180,000 incentive stock options under the Corporation's Stock Option Plan for its senior executive and management team. Each option will vest gradually over a period of two years and will entitle its holder to purchase one common share of Acasti at a price of CDN $0.65 until October 19, 2019. ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti posts higher Q2 net loss of USD3.712m
M2 - Wed Oct 15, 6:52AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) stated on Tuesday that its net loss was USD3.712m for the three-months ended 31 August 2014.
ACST: 0.44 (unch)
Acasti posts 2Q loss
Automated Insights - Wed Oct 15, 4:03AM CDT
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Tuesday reported a loss of $3.3 million, or 3 cents per share, in its fiscal second quarter.
ACST: 0.44 (unch)
Acasti Announces Second Quarter Results
GlobeNewswire - Tue Oct 14, 6:53AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its results for the three and six-months ended August 31, 2014. ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti Announces Positive Top-Line Pharmacokinetic Results
GlobeNewswire - Tue Sep 30, 7:01AM CDT
-- CaPre(R) demonstrated a near dose proportional increase with plasma EPA and DHA levels increasing as dose increases
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
GlobeNewswire - Mon Sep 29, 7:00AM CDT
-- Statistically significant mean placebo-adjusted reduction of triglycerides of 36.4% at 1 gram and 38.6% at 2 gram daily doses of CaPre(R)
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Mallinckrodt Beats on Q3 Earnings and Revenues, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:23PM CDT
Shares of Mallinckrodt plc (MNK) gained 0.46% following the company's third quarter fiscal 2014 (ended Jun 27, 2014) earnings report last week.
MNK: 115.01 (+2.51), ACST: 0.44 (unch), AKRX: 47.28 (-0.25), ACUR: 0.55 (+0.01)
Acasti Pharma (ACST) Jumps: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:46AM CDT
Acasti Pharma (ACST) was a big mover last session, with shares rising over 7% on the day.
MNK: 115.01 (+2.51), ACST: 0.44 (unch), AKRX: 47.28 (-0.25), RDY: 54.15 (-0.01)
Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston
GlobeNewswire - Thu Jul 24, 6:01AM CDT
-- Phase II Open Label Trial results for prescription drug candidate, CaPre(R) to be presented on July 26, 2014 at 12:30 p.m.
ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti swings to Q1 net income of USD1.356m
M2 - Wed Jul 16, 7:41AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) stated on Wednesday its net income of USD1.356m for the first quarter ended 31 May 2014.
ACST: 0.44 (unch)
Acasti Announces First Quarter Results
GlobeNewswire - Wed Jul 16, 3:53AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its financial results for the first quarter ended May 31, 2014. ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
Acasti Pharma Inc. (ACST) Jumps: Stock Rises 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 8:21AM CDT
Acasti Pharma Inc. (ACST) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
CPXX: 3.10 (+0.07), MNK: 115.01 (+2.51), ACST: 0.44 (unch), AKRX: 47.28 (-0.25)
Why Acasti Pharmaceuticals (ACST) Stock Is Up Today
at The Street - Wed Jul 09, 10:48AM CDT
Acasti Pharmaceuticals (ACST) surged Wednesday after the biopharmaceutical company announced it had completed two trials.
ACST: 0.44 (unch)
Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials
GlobeNewswire - Wed Jul 09, 7:09AM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the completion of two trials, the Phase II double-blind, placebo-controlled (TRIFECTA) study and the Pharmacokinetic (PK) trial. ACST: 0.44 (unch), APO.VN: 0.530 (-0.020)
